Literature DB >> 17220802

Successful rescue of refractory, severe antibody mediated rejection with splenectomy.

Bruce Kaplan1, Antonio Gangemi, James Thielke, José Oberholzer, Howard Sankary, Enrico Benedetti.   

Abstract

Antibody-mediated rejection (AMR) commonly occurs after transplantation of ABO-incompatible and sensitized renal transplant. Treatment regimens commonly include a combination of plasmapheresis (PL) and intravenous immunoglobulin (IVIG). However, some cases of AMR remain refractory to treatment. We report a case series of four patients with AMR refractory to standard therapy (ST) who resolved after splenectomy. Four living donor kidney transplant recipients were diagnosed with AMR. Two patients were ABO incompatible, one was cross-match positive and one had no obvious predisposing factors. After failure of therapy with corticosteroids, PL, IVIG, Thymoglobulin, and Rituximab (three patients) or Campath (one patient), AMR was treated with laparoscopic splenectomy. After an average of 11 days of ST, laparoscopic splenectomy was performed for rescue. The urinary output improved immediately in all patients, serum creatinine levels decreased within 48 hr, and ABO titers fell in the ABO-incompatible patient and the cross-match became negative in the two sensitized patients. Splenectomy may play a role in the treatment of AMR refractory to ST.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220802     DOI: 10.1097/01.tp.0000243739.31440.2b

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

1.  A case of desensitization, transplantation, and allograft dysfunction.

Authors:  Colm Magee; Michael Clarkson; Helmut Rennke
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

2.  The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients.

Authors:  A Sicard; T W Phares; H Yu; R Fan; W M Baldwin; R L Fairchild; A Valujskikh
Journal:  Am J Transplant       Date:  2012-03-15       Impact factor: 8.086

3.  Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.

Authors:  Carrie A Schinstock; Andrew J Bentall; Byron H Smith; Lynn D Cornell; Matthew Everly; Manish J Gandhi; Mark D Stegall
Journal:  Am J Transplant       Date:  2018-12-15       Impact factor: 8.086

Review 4.  Sensitized renal transplant recipients: current protocols and future directions.

Authors:  James Gloor; Mark D Stegall
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

Review 5.  Strategies to overcome the ABO barrier in kidney transplantation.

Authors:  Georg A Böhmig; Andreas M Farkas; Farsad Eskandary; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2015-09-01       Impact factor: 28.314

6.  Molecular phenotypes of acute rejection predict kidney graft prognosis.

Authors:  Ondrej Viklicky; Petra Hribova; Hans-Dieter Volk; Janka Slatinska; Jan Petrasek; Stepan Bandur; Eva Honsova; Petra Reinke
Journal:  J Am Soc Nephrol       Date:  2009-09-24       Impact factor: 10.121

7.  Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2014-03-24

8.  ABO Incompatible Kidney Transplantation-Current Status and Uncertainties.

Authors:  Milljae Shin; Sung-Joo Kim
Journal:  J Transplant       Date:  2011-12-10

9.  Laparoscopic splenectomy to salvage renal transplants from severe acute antibody-mediated rejection.

Authors:  Michael Latzko; Sakshi Jasra; Sana Akbar; Harry Sun; Sadanand Palekar
Journal:  Case Rep Transplant       Date:  2012-12-18

10.  Antibody-mediated rejection in kidney transplantation: a review.

Authors:  Chethan Puttarajappa; Ron Shapiro; Henkie P Tan
Journal:  J Transplant       Date:  2012-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.